Possible strategy to prevent recurrence of actinic keratosis after treatment field-direct.

2020

Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

2020

Our experience with prurigo nodularis treated with dupilumab.

2020

Possible role of polycyclic aromatic hydrocarbons in the onset of melanoma: preliminary data.

2019

Assessment of etanercept efficacy in the treatment of psoriatic arthritis: ultrasonography of Achilles tendon

2015

Gender differences in adverse drug reactions in dermatological patients in west Sicily: an epidemiological study

2013

Purpose: The purpose of this study was to show that gender also plays an important role in pharmacokinetics, pharmacodynamics, and drug toxicity. It is only fair to take into account the so-called “gender-based medicine.” Methods: We again selected admission for cutaneous adverse drug reaction (CADRs), from January 2012 to July 2012, in order to detect and verify, in an analytical way, the substantial gender differences in adverse drug reactions in term incidence, clinical manifestations, severity and drugs involved. Results:In the period January–July 2012, at the Department of Dermatology and Sexually Transmitted Disease of A.O.U.P. “Paolo Giaccone” Palermo, 384 patients were admitted, of …

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

2019

Psoriasis impacts the quality of life (QoL) by disrupting overall health and social life. Thus, the use of a QoL evaluation item is crucial in assessing a therapeutic regimen. Also, faster improvements in QoL lead to better patient compliance, but very few studies compare psoriasis traditional and biologic therapies timing. To evaluate how much different systemic therapies improve disease severity and QoL, a retrospective analysis was performed on 56 patients. Subjects were administered different drugs and their vital statistics, psoriasis area severity index (PASI) and PSOdisk were collected at baseline and after 30 days. We found a moderate correlation between PASI and PSOdisk score with …

Real-life practice: rapid improvement in itch symptomatology in patients with atopic dermatitis treated with dupilumab

2019

Sir,Atopic dermatitis is a chronic relapsing inflammatory skin disorder that affects up to 20% of children and 2–5% of the adult population (1). The disease is characterized by erythematous, xeroti...

Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?

2020

Secukinumab efficacy in the treatment of nail psoriasis: a case series

2018

Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis (PsA), and can significantly impair quality of life (QoL). It is typically difficult to treat compared with skin lesions, although several conventional treatment options are available. The aim of this article is to describe our experience in the treatment of nail psoriasis with secukinumab in a case series. Fifteen patients (11 males and 4 females), with moderate-severe plaque psoriasis and nail psoriasis, eligible for systemic therapy, and received secukinumab. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) assessed cutaneous severity. Nail Psoriasis Severity Index (…

Scalp psoriasis: report of efficient treatment with secukinumab

2018

Background: Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population in the world. The scalp is the most common, and frequently the first site of disease involvement. Occasionally it may be the only localization of psoriasis. Objective: Treatment of scalp psoriasis is often unsatisfactory, due to limited available topical therapy and reduced efficacy of some systemic drugs. Biologic therapies are recommended for severe psoriasis, resistant to topical treatment, but evidence from randomized, controlled studies is lacking regarding effectiveness on scalp-localized lesions. The aim of this paper is to show our experience on the efficacy of secukinumab on scalp psoriasi…